“The new agreement is a huge step in helping to ensure global equity of access to the newest and best medicines for HIV as this has been negotiated ahead of the FDA approval for the drug, allowing for the generic version to be produced at the same time as the original production, and available at a decreased price,” said Dr Philippe Duneton, Executive Director a.i. “Furthermore, this medicine could be a game-changer for HIV treatment, partly as patients need take a much smaller dose of it than of other drugs. Fixed dose combinations are also key to reaching and maintaining people living with HIV on quality antiretroviral treatment.”
